{"id":"b01ea9e1-7eb2-41ff-87ea-632d986c63bf","name":"Sentante","slug":"sentante","description":"Sentante is a Vilnius-based medical robotics company developing an endovascular robotic platform with haptic force feedback and real-time guidance for remote vascular interventions. The first endovascular robot to complete an entire procedure in a clinical trial (ESSENTIAL, NCT06537947). Backed by €6M seed funding from Practica Capital and EIC Fund.","status":"private","founded":2017,"hq":"Vilnius, Lithuania","hqLat":54.6870458,"hqLng":25.2829111,"hqGeocodedAt":"2026-08-23T21:07:25.171Z","hqAddress":null,"hqPrecision":null,"website":"sentante.com","fundingTotal":"6500000","type":"hardware","roles":["robot_maker","robot_operator"],"reviewStatus":"reviewed","heatIndex":75,"lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.medtechdive.com/news/sentante-lands-europes-ce-mark-for-endovascular-robot/820918/","title":"Sentante lands Europe's CE mark for endovascular robot","sourceName":"MedTech Dive"},{"url":"https://sentante.com/news/sentante-receives-ce-mark-approval-unlocking-commercialisation-of-its-endovascular-robotic-platform/","date":"2026-05-20","title":"Sentante Receives CE Mark Approval unlocking commercialisation of its Endovascular Robotic platform","sourceName":"Sentante"}],"keyFacts":[{"label":"CE mark (company-claimed)","value":"Secured CE mark approval on May 20 2026 for its endovascular robotic platform, enabling marketing and sales across European markets."},{"label":"Next steps (company-claimed)","value":"Initial market rollout, clinician training and commercial footprint expansion; co-founder Dr. Tomas Baltrunas is quoted on scaling."},{"label":"Platform (company-claimed)","value":"A haptic, device-agnostic endovascular robotic platform for remote vascular procedures with tactile feedback, built to fit existing cath labs."},{"label":"Applications (company-claimed)","value":"Peripheral vascular, neurovascular and cardiovascular procedures."},{"label":"Digital indeflator (company-claimed)","value":"Recently unveiled a digital indeflator for angioplasty and stent deployment."}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-08-08T22:30:17.976Z","updatedAt":"2026-10-13T02:43:26.316Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/sentante","url":"https://registry.deploy.report/companies/sentante","name":"Sentante","description":"Sentante is a Vilnius-based medical robotics company developing an endovascular robotic platform with haptic force feedback and real-time guidance for remote vascular interventions. The first endovascular robot to complete an entire procedure in a clinical trial (ESSENTIAL, NCT06537947). Backed by €6M seed funding from Practica Capital and EIC Fund.","identifier":"b01ea9e1-7eb2-41ff-87ea-632d986c63bf","foundingDate":"2017","address":"Vilnius, Lithuania","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":2,"primary_source_types":["secondary-trade-publication"]}}}